Lodoxamide Explained

Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer.^[1] In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.^[2]

See also

• Nedocromil
• Zaprinast
• Amlexanox
• Pemirolast
• Pamoic acid
• Kynurenic acid
• CXCL17

Notes and References

1. 10.1016/S0161-6420(00)00089-0 . Avunduk . A. M. . Avunduk . M. C. . Kapicioglu . Z. . Akyol . N. . Tavli . L. . Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis . Ophthalmology . 107 . 7 . 1333–1337 . 2000 . 10890862.
2. MacKenzie . AE . Caltabiano . G . Kent . TC . Jenkins . L . McCallum . JE . Hudson . BD . Nicklin . SA . Fawcett . L . Markwick . R . Charlton . SJ . Milligan . G . The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. . Molecular Pharmacology . 85 . 1 . 2014 . 0026-895X . 24113750 . 3868900 . 10.1124/mol.113.089482 . 91–104.